The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF
Open accessAbstract
To fully assess the role of VEGF-A in tumor angiogenesis, antibodies that can block all sources of vascular endothelial growth factor (VEGF) are desired. Selectively targeting tumor-derived VEGF overlooks the contribution of host stromal VEGF. Other strategies, such as targeting VEGF receptors directly or using receptor decoys, result in inhibiting not only VEGF-A but also VEGF homologues (e.g. placental growth factor, VEGF-B, and VEGF-C), which may play a role in angiogenesis. Here we report the identification of novel anti-VEGF antibodies, B20 and G6, from synthetic antibody phage libraries, which block both human and murine VEGF action in vitro. Their affinity-improved variants completely inhibit three human tumor xenografts in mice of skeletal muscle, colorectal, and pancreatic origins (A673, HM-7, and HPAC). Avastin, which only inhibits the tumor-derived human VEGF, is approximately 90% effective at inhibiting HM-7 and A673 growth but is <50% effective at inhibiting HPAC growth. Indeed, HPAC tumors contain more host stroma invasion and stroma-derived VEGF than other tumors. Thus, the functional contribution of stromal VEGF varies greatly among tumors, and systemic blockade of both tumor and stroma-derived VEGF is sufficient for inhibiting the growth of tumor xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citationHeterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Self-citationCarmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,672
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Self-citationMaking antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946
VEGF is required for growth and survival in neonatal mice
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 915
Self-citationVasculogenic mimicry and tumour-cell plasticity: lessons from melanoma
Hendrix, M. J. C., Seftor, E. A., Hess, A. R., & Seftor, R. E. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1092 · Cited by 824
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Plaisance, S., De Mol, M., Bono, F., et al. (2003) · Nature Medicine · doi:10.1038/nm884 · Cited by 773
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Self-citationAnalysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)
Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T. F., Pelletier, N., & Ferrara, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002016200 · Cited by 620
Self-citationMeyer, M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.2.363 · Cited by 509
Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor
Wiesmann, C., Fuh, G., Christinger, H. W., Eigenbrot, C., Wells, J. A., & de Vos, A. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80456-0 · Cited by 486
Self-citationMuller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C., & de Vos, A. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7192 · Cited by 452
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448
Self-citationInoue, M., Hager, J. H., Ferrara, N., Gerber, H.-P., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Self-citationBellomo, D., Headrick, J. P., Silins, G. U., Paterson, C. A., Thomas, P. S., Gartside, M., Mould, A., Cahill, M. M., Tonks, I. D., Grimmond, S. M., et al. (2000) · Circulation Research · doi:10.1161/01.res.86.2.e29 · Cited by 333
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Ring, L., New, T., Zabski, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398399 · Cited by 312
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Dong, J., Grunstein, J., Tejada, M., Peale, F., Frantz, G., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 295
Self-citationMuller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., & de Vos, A. M. (1998) · Structure · doi:10.1016/s0969-2126(98)00116-6 · Cited by 264
Fuh, G., Li, B., Crowley, C., Cunningham, B., & Wells, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.18.11197 · Cited by 259
Self-citationTumor angiogenesis and accessibility: Role of vascular endothelial growth factor
JAIN, R. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70063-8 · Cited by 256
Hanahan, D., Christofori, G., Naik, P., & Arbeit, J. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00401-7 · Cited by 253
Gerber, H., Kowalski, J., Sherman, D. A., Eberhard, D. A., & Ferrara, N. (2000) · PubMed · Cited by 251
Self-citationGrunstein, J., Roberts, W. G., Mathieu-Costello, O. A., Hanahan, D., & Johnson, R. S. (1999) · PubMed · Cited by 247
Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor
Jain, R. K. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37265 · Cited by 242
Barberá‐Guillem, E., Nyhus, J. K., Wolford, C. C., Friece, C., & Sampsel, J. W. (2002) · PubMed · Cited by 233
Lee, C. V., Liang, W.-C., Dennis, M. S., Eigenbrot, C., Sidhu, S. S., & Fuh, G. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.05.051 · Cited by 227
Self-citationOverview of Antibody Phage-Display Technology and Its Applications
Hoogenboom, H. R. (2003) · Antibody Phage Display · doi:10.1385/1-59259-240-6:001 · Cited by 187
Hlatky, L., Tsionou, C., Hahnfeldt, P., & Coleman, C. N. (1994) · PubMed · Cited by 187
Structure and Function of Vascular Endothelial Growth Factor Receptor-1 and -2
Shibuya, M., Ito, N., & Claesson-Welsh, L. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_4 · Cited by 159
Kishimoto, J., Ehama, R., Ge, Y., Kobayashi, T., Nishiyama, T., Detmar, M. J., & Burgeson, R. E. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64522-1 · Cited by 86
Samson, M., Peale, F. V., Jr., Frantz, G. D., Rioux-Leclercq, N. C., Meyts, E. R., & Ferrara, N. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032024 · Cited by 81
Self-citationViloria‐Petit, A., Miquerol, L., Yu, J. L., Gertsenstein, M., Sheehan, C., May, L., Henkin, J., Lobe, C., Nagy, A., Kerbel, R. S., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg408 · Cited by 71
Shi, Y., & Ferrara, N. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9966 · Cited by 39
Self-citationRodriguez, C. R., Fei, D. T., Keyt, B. A., & Baly, D. L. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00131-8 · Cited by 33
Cited by
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Self-citationInhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Self-citationFERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Self-citation
Metadata
- Authors
- Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., & Fuh, G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 281
- Issue
- 2
- Pages
- 951-961
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2144718958
- Cited by
- 346
- References
- 46
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.